$27.19
-0.41-1.49%
At close: Dec 17, 4:00 PM EST
$27.15
-0.04-0.15%
After Hours: 7:51 PM EST
Comments
Loading...
Caris Life Sciences Analyst Ratings and Price Targets | NASDAQ:CAI | Benzinga
Caris Life Sciences Inc has a consensus price target of $34.43 based on the ratings of 7 analysts. The high is $42 issued by Citigroup on August 13, 2025. The low is $28 issued by Canaccord Genuity on December 2, 2025. The 3 most-recent analyst ratings were released by Canaccord Genuity, Guggenheim, and Evercore ISI Group on December 2, 2025, August 13, 2025, and August 13, 2025, respectively. With an average price target of $34.67 between Canaccord Genuity, Guggenheim, and Evercore ISI Group, there's an implied 27.69% upside for Caris Life Sciences Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Canaccord Genuity
Guggenheim
Evercore ISI Group
Citigroup
TD Cowen
1calculated from analyst ratings
Analyst Ratings for Caris Life Sciences
FAQ
What is the target price for Caris Life Sciences (CAI) stock?
The latest price target for Caris Life Sciences (NASDAQ:CAI) was reported by Canaccord Genuity on December 2, 2025. The analyst firm set a price target for $28.00 expecting CAI to rise to within 12 months (a possible 3.13% upside). 10 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Caris Life Sciences (CAI)?
The latest analyst rating for Caris Life Sciences (NASDAQ:CAI) was provided by Canaccord Genuity, and Caris Life Sciences initiated their hold rating.
When was the last upgrade for Caris Life Sciences (CAI)?
There is no last upgrade for Caris Life Sciences
When was the last downgrade for Caris Life Sciences (CAI)?
There is no last downgrade for Caris Life Sciences.
When is the next analyst rating going to be posted or updated for Caris Life Sciences (CAI)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Caris Life Sciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Caris Life Sciences was filed on December 2, 2025 so you should expect the next rating to be made available sometime around December 2, 2026.
Is the Analyst Rating Caris Life Sciences (CAI) correct?
While ratings are subjective and will change, the latest Caris Life Sciences (CAI) rating was a initiated with a price target of $0.00 to $28.00. The current price Caris Life Sciences (CAI) is trading at is $27.15, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
